Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Prior studies have suggested that loss of plasma cell CD56 expression in multiple myeloma defines a unique patient subset and that CD56 expression reliably discriminates between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). We conducted a study of 68 untreated patients with MM from a single institution to define the clinicopathological correlates of CD56 expression. We find CD56 expression in 55% of MM. Lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. Strong CD56 expression can also be found in MGUS and does not help to distinguish from MM.
Mathew
P
P
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Ahmann
G J
GJ
Witzig
T E
TE
Roche
P C
PC
Kyle
R A
RA
Greipp
P R
PR
D015703:Antigens, CD / Q000378:metabolism*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D019002:CD56 Antigen; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000276:immunology*; D011379:Prognosis; D016019:Survival Analysis
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen